Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54

HOS-116511 · Präparat HOS-094447

53 Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine didanosine AUC ↓ 9% PREZISTA co-administered with 400 mg once daily didanosine Cmin ND low dose ritonavir and didanosine didanosine Cmax ↓ 16% can be used without dose darunavir AUC ↔ adjustments. darunavir Cmin ↔ Didanosine is to be administered darunavir Cmax ↔ on an empty stomach, thus it should be administered 1 hour before or 2 hours after PREZISTA/ritonavir given with food. Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may 245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when PREZISTA tenofovir Cmax ↑ 24% co-administered with low dose # darunavir AUC ↑ 21% ritonavir is given in combination # darunavir Cmin ↑ 24% with tenofovir disoproxil, # particularly in patients with darunavir Cmax ↑ 16% underlying systemic or renal (↑ tenofovir from effect on MDR-1 disease, or in patients taking transport in the renal tubules) nephrotoxic agents. Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of alafenamide Tenofovir ↑ emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with PREZISTA with low dose ritonavir. Abacavir Not studied. Based on the different PREZISTA co-administered with Emtricitabine elimination pathways of the other NRTIs low dose ritonavir can be used Lamivudine zidovudine, emtricitabine, stavudine, with these NRTIs without dose Stavudine lamivudine, that are primarily renally adjustment. Zidovudine excreted, and abacavir for which metabolism is not mediated by CYP450, no interactions are expected for these medicinal compounds and PREZISTA co-administered with low dose ritonavir. Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs) Efavirenz efavirenz AUC ↑ 21% Clinical monitoring for central 600 mg once daily efavirenz Cmin ↑ 17% nervous system toxicity associated efavirenz Cmax ↑ 15% with increased exposure to # darunavir AUC ↓ 13% efavirenz may be indicated when # darunavir Cmin ↓ 31% PREZISTA co-administered with # low dose ritonavir is given in darunavir Cmax ↓ 15% combination with efavirenz. (↑ efavirenz from CYP3A inhibition) (↓ darunavir from CYP3A induction) Efavirenz in combination with PREZISTA/ritonavir 800/100 mg once daily may result in sub-optimal darunavir Cmin. If efavirenz is to be used in combination with PREZISTA/ritonavir, the PREZISTA/ritonavir 600/100 mg twice daily regimen should be used (see section 4.4). Etravirine etravirine AUC ↓ 37% PREZISTA co-administered with 100 mg twice daily etravirine Cmin ↓ 49% low dose ritonavir and etravirine etravirine Cmax ↓ 32% 200 mg twice daily can be used darunavir AUC ↑ 15% without dose adjustments. darunavir Cmin ↔ darunavir Cmax ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476) stavudine (HOS-088080) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) efavirenz (HOS-087947) ritonavir (HOS-084521) abacavir (HOS-088077) emtricitabine (HOS-085840)